

Speaking Engagements | July 30 - 31, 2025

FDA and HHS Activity Round-Up: An Examination of New Agency Priorities and Initiatives Impacting the Life Sciences Industry

SPEAKERS

Judith L. O'Grady

July 30 – 31, 2025

Judy O'Grady will be presenting during the American Conference Institute's 12th Annual Summit for Women Leaders in Life Sciences Law in Boston MA.

With leadership shifts and policy changes at the FDA and HHS, the life sciences industry faces a period of uncertainty and potential transformation. This panel will explore the latest developments, potential roadblocks, and emerging opportunities under the new administration. Discussion topics include:

- Exploring the implications of RFK, Jr.'s plans to shift NIH focus from infectious disease to chronic disease.
- Examining the projected impact of new HHS leadership on vaccine policy, clinical trials, drug approvals, drug pricing, and more.
- Status of the "Make America Healthy Again" Commission: how could this initiative reshape federal policies and regulations impacting the life sciences industry?
- CMS and Medicare/Medicaid under new leadership—what are the agency's new key priorities, and how will they affect the industry?
- Updates on delays, accelerations, and pivots—will pending FDA initiatives stay on track, or is a new regulatory agenda on the horizon?
- The future of rare disease initiatives—will funding and policy support continue or stall?
- AI and the FDA—how will regulatory oversight evolve, and what does it mean for innovation in life sciences?

RELATED INDUSTRIES + PRACTICES

- [Health Care + Life Sciences](#)
- [Life Sciences Transactions](#)